Literature DB >> 11809983

Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals.

G J M Herder1, P Verboom, E F Smit, P C M van Velthoven, J H A M van den Bergh, C D Colder, I van Mansom, J C van Mourik, P E Postmus, G J J Teule, O S Hoekstra.   

Abstract

BACKGROUND: A study was undertaken to investigate the clinical practice, yield, and costs of preoperative staging in patients with suspected NSCLC and to obtain baseline data for prospective studies on the cost effectiveness of (18)F-fluorodeoxyglucose positron emission tomography in the management of these patients.
METHODS: A retrospective study of the medical records of all patients with suspected NSCLC was performed during a 2 year interval (1993-4) in an academic and a large community hospital.
RESULTS: Three hundred and ninety five patients with suspected NSCLC were identified; 58 were deemed to be medically inoperable and 337 patients proceeded to the staging process. Staging required a mean (SD) of 5.1 (1.5) diagnostic tests per patient (excluding thoracotomy) carried out over a median period of 20 days (IQR 10-31). Many of the tests (including both invasive and non-invasive) were done because previous imaging tests had suggested metastases, and in most cases the results of initial tests proved to be false positives. After clinical staging, 168 patients were considered to be resectable (stage I/II) and 144 patients underwent surgery with curative intent. At surgery 33 patients (23% of those who underwent surgery) were found to have irresectable lesions and 19 (13%) had a benign lesion. Surgery was also considered to be futile in 22 patients (15%) who developed metastases or local recurrence within 12 months following radical surgery. Hospital admission was responsible for most of the costs.
CONCLUSION: In many patients staging involved considerable effort in terms of the number of diagnostic tests, the duration of the staging period and the cost, with limited success in preventing futile surgery. Failures relate to the quality of diagnostic preparation at every level of the TNM staging system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809983      PMCID: PMC1746187          DOI: 10.1136/thorax.57.1.11

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

1.  The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer.

Authors:  G M Tsang; D C Watson
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

2.  Management of lung cancer in South East Scotland.

Authors:  R J Fergusson; A Gregor; R Dodds; G Kerr
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

3.  The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions.

Authors:  P Tugwell; K J Bennett; D L Sackett; R B Haynes
Journal:  J Chronic Dis       Date:  1985

Review 4.  Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report.

Authors:  P Goldstraw; P Rocmans; D Ball; N Barthelemy; J Bonner; M Carette; N Choi; B Emami; D Grunenwald; M Hazuka
Journal:  Lung Cancer       Date:  1994-11       Impact factor: 5.705

5.  Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations.

Authors:  J M Grimshaw; I T Russell
Journal:  Lancet       Date:  1993-11-27       Impact factor: 79.321

6.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.

Authors:  B A Dwamena; S S Sonnad; J O Angobaldo; R L Wahl
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

Review 7.  "Incomplete resection" in non-small cell lung cancer: need for a new definition. Canadian Lung Oncology Group.

Authors:  Y Lacasse; H C Bucher; E Wong; L Griffith; S Walter; R J Ginsberg; G H Guyatt
Journal:  Ann Thorac Surg       Date:  1998-01       Impact factor: 4.330

8.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

Authors:  R M Pieterman; J W van Putten; J J Meuzelaar; E L Mooyaart; W Vaalburg; G H Koëter; V Fidler; J Pruim; H J Groen
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

9.  Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography.

Authors:  H van Tinteren; O S Hoekstra; E F Smit; P Verboom; M Boers
Journal:  Control Clin Trials       Date:  2001-02

Review 10.  [Consensus conference on the diagnosis of lung carcinoma].

Authors:  N van Zandwijk
Journal:  Ned Tijdschr Geneeskd       Date:  1991-10-12
View more
  7 in total

1.  Do we need randomised trials to evaluate diagnostic procedures? For.

Authors:  H Van Tinteren; O S Hoekstra; M Boers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-29       Impact factor: 9.236

Review 2.  Endoscopic ultrasound advances, part 1: diagnosis.

Authors:  Edward Kim; Jennifer J Telford
Journal:  Can J Gastroenterol       Date:  2009-09       Impact factor: 3.522

3.  Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.

Authors:  Stephen Deppen; Joe B Putnam; Gabriela Andrade; Theodore Speroff; Jonathan C Nesbitt; Eric S Lambright; Pierre P Massion; Ron Walker; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2011-05-18       Impact factor: 4.330

Review 4.  Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound.

Authors:  Neal Navani; Stephen G Spiro; Sam M Janes
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

5.  Impact of EBUS-TBNA on modalities for tissue acquisition in patients with lung cancer.

Authors:  R J José; P Shaw; M Taylor; D R Lawrence; P J George; S M Janes; N Navani
Journal:  QJM       Date:  2013-11-19

6.  SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.

Authors:  Bernd Schmidt; Volker Liebenberg; Dimo Dietrich; Thomas Schlegel; Christoph Kneip; Anke Seegebarth; Nadja Flemming; Stefanie Seemann; Jürgen Distler; Jörn Lewin; Reimo Tetzner; Sabine Weickmann; Ulrike Wille; Triantafillos Liloglou; Olaide Raji; Martin Walshaw; Michael Fleischhacker; Christian Witt; John K Field
Journal:  BMC Cancer       Date:  2010-11-03       Impact factor: 4.430

7.  A comparison of endoscopic ultrasound guided biopsy and positron emission tomography with integrated computed tomography in lung cancer staging.

Authors:  S S Larsen; P Vilmann; K Krasnik; Asger Dirksen; P Clementsen; Birgit G Skov; Grete Krag Jacobsen; U Lassen; Annika Eigtved; Anne Kiil Berthelsen; J Mortensen; Liselotte Hoejgaard
Journal:  Curr Health Sci J       Date:  2009-03-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.